After-Hours Stock Movers 09/14: (AERI) (ACTG) (ACRX) Higher; (SBLK) (CLC) (SRPT) Lower (more...)
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Aerie Pharma (NASDAQ: AERI) 65% HIGHER; reported the successful 90-day primary efficacy results of its 12-month Phase 3 “Mercury 1” clinical trial for its fixed-dose combination product candidate, Roclatan. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening.
Acacia Research (NASDAQ: ACTG) 16% HIGHER; reportedly won a $22 million judgement against Apple
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) 16% HIGHER; will announce the results of its multicenter, open-label Phase 3 clinical study of ARX-04, known as SAP303. The study was conducted in patients 40 years and older who have moderate-to-severe acute pain following a surgical procedure. Patients were administered one dose of ARX-04 (sufentanil sublingual tablet, 30 mcg) every 60 minutes, as needed for pain management, for up to 12 hours.
Lakeland Industries (NASDAQ: LAKE) 10.7% HIGHER; reported Q2 EPS of $0.20, $0.10 better than the analyst estimate of $0.10. Revenue for the quarter came in at $22.3 million versus the consensus estimate of $22.01 million.
Apogee Enterprises (NASDAQ: APOG) 6.5% HIGHER; reported Q2 EPS of $0.77, $0.10 better than the analyst estimate of $0.67. Revenue for the quarter came in at $278.5 million versus the consensus estimate of $268.05 million. GUIDANCE: Apogee Enterprises sees FY2017 EPS of $2.80-$2.90, versus prior guidance of $2.70-$2.85 and the consensus of $2.83.
Star Bulk Carriers (NASDAQ: SBLK) 4% LOWER; reported Q2 EPS of ($0.69), $0.03 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $52.65 million versus the consensus estimate of $41.26 million. As of August 31, 2016 we have entered into Restructuring Letter Agreements (the "RLAs") with all 15 banks and export credit agencies (the "Lenders") providing our senior secured credit facilities, to waive 100% of the principal repayments for 25 months, for the period commencing June 1st 2016 and ending June 30th 2018 and waive or substantially relax financial covenants until December 31st 2019. The agreements are subject to certain conditions precedent, including an equity raise of not less than $50.0 million of net proceeds to be completed by September 30th 2016. Also announced it plans to make an underwritten public offering for $51.5 million gross proceeds of its common stock.
CLARCOR (NYSE: CLC) 1.4% LOWER; reported Q3 EPS of $0.73, $0.04 better than the analyst estimate of $0.69. Revenue for the quarter came in at $331.4 million versus the consensus estimate of $337.91 million. GUIDANCE: CLARCOR sees FY2016 EPS of $2.57-$2.63, versus prior guidance of $2.60-$2.80 and the consensus of $2.66. Sees sales of $1,380 to $1,390 million versus prior of $1,375 to $1,415 million.
Sarepta Therapeutics (NASDAQ: SRPT) 1.4% LOWER; giving up some intra-day gains, Jefferies analysts said they see not impact on approvability of eteplirsen, citing a KOL. Reiterated an Underperform rating and price target of $7.00.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Notable Analyst Rating Changes 10/21: (CHK) (NRF) (AVT) Upgraded; (MEMP) (YHOO) (WWAV) Downgraded
- Streetinsider.com's Hot Lunchtime Reads 10/20: (GME) (BA) (PLD) (LULU)
- Notable 52-Week Highs and Lows 10/20: (ABEO) (LSTR) (STI) High; (TSCO) (SYNT) (BJRI) Low